SGEN Seattle Genetics, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

SGEN [NASD]

Seattle Genetics, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-1.50	Insider Own	0.90%	Shs Outstand	173.41M	Perf Week	-3.50%
Market Cap	28.15B	Forward P/E	-	EPS next Y	-0.33	Insider Trans	-67.04%	Shs Float	172.74M	Perf Month	-11.44%
Income	-255.70M	PEG	-	EPS next Q	-0.55	Inst Own	94.31%	Short Float	2.31%	Perf Quarter	1.76%
Sales	1.02B	P/S	27.72	EPS this Y	32.10%	Inst Trans	6.46%	Short Ratio	3.19	Perf Half Y	36.66%
Book/sh	10.46	P/B	15.34	EPS next Y	84.40%	ROA	-11.90%	Target Price	179.82	Perf Year	108.19%
Cash/sh	5.10	P/C	31.43	EPS next 5Y	-	ROE	-14.10%	52W Range	65.44 - 187.99	Perf YTD	40.43%
Dividend	-	P/FCF	-	EPS past 5Y	-9.20%	ROI	-11.80%	52W High	-14.65%	Beta	1.34
Dividend %	-	Quick Ratio	4.40	Sales past 5Y	26.20%	Gross Margin	90.10%	52W Low	145.19%	ATR	6.15
Employees	1605	Current Ratio	4.70	Sales Q/Q	27.30%	Oper. Margin	-32.90%	RSI (14)	40.21	Volatility	2.90% 3.60%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	75.10%	Profit Margin	-25.20%	Rel Volume	0.58	Prev Close	161.80
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Jul 30 AMC	Payout	-	Avg Volume	1.25M	Price	160.45
Recom	2.20	SMA20	-6.77%	SMA50	-3.29%	SMA200	22.21%	Volume	727,158	Change	-0.83%

Jul-31-20

Reiterated

H.C. Wainwright

Buy

$175 → $200

Jul-24-20

Downgrade

Piper Sandler

Overweight → Neutral

May-26-20

Initiated

JMP Securities

Mkt Outperform

$185

May-01-20

Upgrade

Guggenheim

Neutral → Buy

May-01-20

Reiterated

Needham

Buy

$157 → $163

Feb-18-20

Downgrade

Barclays

Overweight → Equal Weight

$124

Feb-12-20

Reiterated

H.C. Wainwright

Buy

$140 → $150

Feb-11-20

Reiterated

Goldman

Buy

$126 → $165

Jan-28-20

Initiated

BMO Capital Markets

Outperform

Jan-27-20

Initiated

BMO Capital Markets

Outperform

Jan-02-20

Downgrade

Guggenheim

Buy → Neutral

Dec-10-19

Initiated

Morgan Stanley

Equal-Weight

Dec-03-19

Resumed

BofA/Merrill

Neutral

Oct-22-19

Reiterated

H.C. Wainwright

Buy

$98 → $140

Oct-22-19

Reiterated

BofA/Merrill

Underperform

$58 → $83

Sep-27-19

Upgrade

Goldman

Neutral → Buy

$78 → $100

Aug-26-19

Initiated

BTIG Research

Neutral

Jul-18-19

Initiated

Deutsche Bank

Hold

$79

Jul-17-19

Upgrade

Piper Jaffray

Neutral → Overweight

$64 → $75

Apr-11-19

Initiated

Stifel

Hold

$70

Aug-06-20 08:00AM	Seattle Genetics Achieves Milestone Payment Under Antibody-Drug Conjugate Collaboration with GlaxoSmithKline Triggered by BLENREP (belantamab mafodotin-blmf) FDA Approval Business Wire
Jul-31-20 08:32PM	Seattle Genetics (SGEN) Q2 2020 Earnings Call Transcript Motley Fool
11:16AM	Seattle Genetics (SGEN) Q2 Earnings Beat, Adcetris Aids Sales Zacks
Jul-30-20 05:15PM	Seattle Genetics (SGEN) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:02PM	Seattle Genetics Reports Second Quarter 2020 Financial Results Business Wire
Jul-28-20 06:23AM	4 Reasons AstraZeneca Gave Daiichi Sankyo Another $1 Billion Upfront Motley Fool
Jul-24-20 12:10PM	Piper Sandler Downgrades Seattle Genetics, Says Visibility Limited On Value Creation Benzinga
Jul-23-20 12:33PM	Seattle Genetics (SGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release Zacks
Jul-19-20 08:58AM	What Can We Learn About Seattle Genetics' (NASDAQ:SGEN) CEO Compensation? Simply Wall St.
Jul-12-20 01:20PM	Did Hedge Funds Make The Right Call On Seattle Genetics, Inc. (SGEN) ? Insider Monkey
Jul-09-20 08:00AM	Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2020 Financial Results on July 30, 2020 Business Wire
Jul-06-20 10:28AM	Seattle Genetics' Adcetris Progresses Well Amid Competition Zacks
Jul-03-20 10:03AM	Why Seattle Genetics Shares Climbed 48.7% in the First Half Motley Fool
Jun-30-20 07:41AM	The Daily Biotech Pulse: Verrica Flags Potential Regulatory Delay, Back-To-Back FDA Approvals For Merck's Keytruda, OncoCyte Stalls Lung Nodule Malignancy Test Benzinga
Jun-29-20 04:30PM	Seattle Genetics Announces Positive Topline Results from Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer Business Wire
Jun-23-20 09:00PM	Edited Transcript of SGEN.OQ earnings conference call or presentation 30-Apr-20 8:30pm GMT Thomson Reuters StreetEvents
Jun-22-20 11:00AM	Here's My Take on Seattle Genetics TheStreet.com
08:12AM	Dow Jones Futures Slash Losses: Stock Market Rally Faces Coronavirus Wave; Apple WWDC, Tesla News In Focus Investor's Business Daily
Jun-18-20 08:00AM	Seattle Genetics Announces Initiation of Phase 1 Clinical Trials for Two Novel Antibody-Based Drug Candidates Business Wire
Jun-09-20 06:11PM	Do Hedge Funds Love Seattle Genetics, Inc. (SGEN)? Insider Monkey
Jun-03-20 08:00AM	Seattle Genetics to Present at Goldman Sachs 41st Annual Global Healthcare Conference Business Wire
May-30-20 11:31AM	Why Is Seattle Genetics (SGEN) Up 14.6% Since Last Earnings Report? Zacks
May-29-20 08:00AM	Seattle Genetics Announces Positive Results from Exploratory Analyses of HER2CLIMB for TUKYSA (tucatinib) in Brain Metastases Patients With HER2-Positive Breast Cancer Business Wire
May-22-20 07:00PM	Anterix and Bausch Holding See Activist Action Barrons.com
May-19-20 01:02PM	Charting a headline breakout attempt, S&P 500 nails major resistance (2,954) MarketWatch
May-15-20 01:20PM	Seattle Genetics' Adcetris Label Expands in EU for Lymphoma Zacks
11:20AM	Nasdaq ETF (QQQ) Joins $100 Billion Club: 10 Stock Winners Zacks
May-14-20 08:00AM	Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Receives European Commission Approval for Treatment of Adult Patients with Previously Untreated Systemic Anaplastic Large Cell Lymphoma Business Wire
May-13-20 05:12PM	Seattle Genetics Highlights Data from Expanding Oncology Portfolio During Virtual Scientific Program of the 2020 ASCO Annual Meeting Business Wire
May-12-20 08:00AM	Seattle Genetics Announces the Approval of TUKYSA (tucatinib) in Switzerland for the Treatment of Patients with Metastatic HER2-Positive Breast Cancer Business Wire
May-09-20 02:19PM	The Nasdaq is now up for the year here are the indexs best-performing stocks MarketWatch
May-08-20 10:39AM	Arena Pharmaceuticals (ARNA) Q1 Loss Narrower Than Expected Zacks
May-07-20 05:42PM	Analysts See Seattle Genetics Profitable in 2022 GuruFocus.com
May-06-20 11:34AM	Industry Analysts Just Upgraded Their Seattle Genetics, Inc. (NASDAQ:SGEN) Revenue Forecasts By 10% Simply Wall St.
May-05-20 08:00AM	Seattle Genetics to Present at the BofA Securities Virtual Health Care Conference 2020 Business Wire +6.21%
May-04-20 01:25PM	Seattle Genetics (SGEN) Q1 Earnings Beat, Adcetris Aids Sales Zacks +6.95%
11:45AM	Seattle Genetics Soars on Cancer Drugs: Here's How to Play the Stock TheStreet.com
May-01-20 02:30PM	Seattle Genetics Inc (SGEN) Q1 2020 Earnings Call Transcript Motley Fool +6.13%
Apr-30-20 05:15PM	Seattle Genetics (SGEN) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:02PM	Seattle Genetics Reports First Quarter 2020 Financial Results Business Wire
11:12AM	Alkermes' (ALKS) Q1 Earnings Increase Y/Y, Revenues Beat Zacks
Apr-29-20 12:00PM	Here's Why Seattle Genetics (SGEN) is a Great Momentum Stock to Buy Zacks
10:05AM	Biotech Stocks Earnings Roster for Apr 30: AMGN, GILD & More Zacks
Apr-28-20 12:11PM	Will Seattle Genetics Continue to Surge Higher? Zacks
Apr-24-20 08:00AM	Seattle Genetics Announces Change to Virtual Format for 2020 Annual Meeting Business Wire
Apr-23-20 12:32PM	Analysts Estimate Seattle Genetics (SGEN) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-22-20 02:20PM	Shares of Immunomedics rise 1% on FDA approval of breast-cancer drug MarketWatch
10:00AM	Seattle Genetics (NASDAQ:SGEN) Is In A Strong Position To Grow Its Business Simply Wall St.
Apr-21-20 12:34PM	With FDA Approvals in Hand, These 2 Biotech Stocks Are on Wall Streets Radar TipRanks
Apr-20-20 11:42AM	Seattle Genetics Gets Early FDA Nod for Breast Cancer Drug Zacks
07:21AM	Seattle Genetics Breast Cancer Drug Approved Months Ahead of Schedule SmarterAnalyst
Apr-17-20 02:46PM	Seattle Genetics' stock rises on early FDA nod for breast-cancer drug MarketWatch
02:27PM	Seattle Genetics Announces U.S. FDA Approval of TUKYSA (tucatinib) for People with Advanced Unresectable or Metastatic HER2-Positive Breast Cancer Business Wire
02:08PM	Seattle Genetics wins early U.S. approval for $18,500 breast cancer therapy Reuters
Apr-16-20 04:38PM	These Highly Rated Medical Stocks Broke Out Under Coronavirus Limelight Investor's Business Daily +6.69%
Apr-13-20 08:00AM	Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2020 Financial Results on April 30, 2020 Business Wire
Apr-08-20 09:59AM	3 Blue-Chip Biotech Stocks Hitting New Highs Investopedia
08:00AM	Seattle Genetics to Webcast Virtual Fireside Chat at Needham Healthcare Conference Business Wire
Apr-07-20 08:29AM	Amazon, Vertex Lead 5 Top Stocks Entering Buy Zones Investor's Business Daily
Apr-03-20 12:06PM	Seattle Genetics Issue Update on Padcev Label Expansion Study Zacks
Apr-02-20 04:44PM	Stock Indexes Jump As Jobless Claims Soar Again Investor's Business Daily +6.68%
04:37PM	Biotech Nears A Breakout As FDA Mulls Speedy Approval For Cancer Drug Investor's Business Daily
11:04AM	Seattle Genetics Nears Buy Point Investor's Business Daily Video
08:00AM	Seattle Genetics Announces Potential Accelerated Approval Pathway in the U.S. for PADCEV (enfortumab vedotin-ejfv) in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer Business Wire
Mar-17-20 05:54PM	Hedge Funds Have Never Been This Bullish On Seattle Genetics, Inc. (SGEN) Insider Monkey +5.20%
08:59AM	Is There An Opportunity With Seattle Genetics, Inc.'s (NASDAQ:SGEN) 46% Undervaluation? Simply Wall St.
Mar-10-20 08:00AM	Seattle Genetics to Webcast Virtual Fireside Chat at Barclays Global Healthcare Conference Business Wire
Mar-07-20 11:30AM	Why Is Seattle Genetics (SGEN) Down 3.2% Since Last Earnings Report? Zacks
Mar-02-20 08:00AM	Seattle Genetics Announces Cancellation of Presentation and Webcast at the Cowen 40th Annual Healthcare Conference Business Wire
Feb-26-20 08:00AM	Seattle Genetics to Present at the Cowen 40th Annual Healthcare Conference Business Wire
Feb-19-20 05:12PM	Seattle Genetics bladder drug gets breakthrough therapy designation American City Business Journals
09:21AM	Biotech Stock Roundup: INCY's Solid Q4 Results, EPZM & SGEN's Pipeline Updates Zacks
08:28AM	Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for PADCEV (enfortumab vedotin-ejfv) in Combination with Pembrolizumab in First-Line Advanced Bladder Cancer PR Newswire
08:12AM	Seattle Genetics and Astellas Receive FDA Breakthrough Therapy Designation for PADCEV (enfortumab vedotin-ejfv) in Combination with Pembrolizumab in First-Line Advanced Bladder Cancer Business Wire
Feb-13-20 08:00AM	Seattle Genetics Announces FDA Filing Acceptance for Priority Review of Tucatinib New Drug Application (NDA) for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer Business Wire
Feb-12-20 09:18AM	The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data Benzinga
Feb-11-20 08:00AM	Seattle Genetics and Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV (enfortumab vedotin-ejfv) in Combination with Immune Therapy Pembrolizumab as Investigational First-Line Treatment for Advanced Bladder Cancer Business Wire
Feb-10-20 07:01PM	Edited Transcript of SGEN earnings conference call or presentation 6-Feb-20 9:30pm GMT Thomson Reuters StreetEvents
05:00PM	Seattle Genetics and Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV (enfortumab vedotin-ejfv) in Combination with Immune Therapy Pembrolizumab as Investigational First-Line Treatment for Advanced Bladder Cancer PR Newswire
10:51AM	Seattle Genetics, Inc. Consensus Forecasts Have Become A Little Darker Since Its Latest Report Simply Wall St.
09:37AM	3 Nasdaq 100 Stocks With Excellent Upside Potential Investopedia
Feb-07-20 11:15AM	Seattle Genetics (SGEN) Q4 Earnings Top, Adcetris Drives Sales Zacks
Feb-06-20 05:25PM	Seattle Genetics (SGEN) Reports Q4 Loss, Tops Revenue Estimates Zacks
05:07PM	Biotech Giant Crushes Sales Estimates And Posts A Profit But Shares Dive Investor's Business Daily
04:02PM	Seattle Genetics Reports Fourth Quarter and Full Year 2019 Financial Results Business Wire
02:30PM	Seattle Genetics, Inc. to Host Earnings Call ACCESSWIRE
Feb-05-20 09:45AM	Why Seattle Genetics (SGEN) Might Surprise This Earnings Season Zacks +6.09%
Jan-31-20 08:00AM	EMA Validates Seattle Genetics Marketing Authorization Application for Tucatinib for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer Business Wire
Jan-30-20 12:31PM	Seattle Genetics (SGEN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
Jan-21-20 06:13PM	Roche's (RHHBY) Lymphoma Drug Polivy Gets Approval in Europe Zacks
08:30AM	Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2019 Financial Results on February 6, 2020 Business Wire
08:00AM	Seattle Genetics Achieves Milestone Following European Commission Approval of Roches Polivy® (Polatuzumab Vedotin) Business Wire
Jan-20-20 09:32AM	Seattle Genetics Up More Than 40% in the Past Year: Here's Why Zacks
Jan-16-20 08:56AM	How Much is Seattle Genetics, Inc.'s (NASDAQ:SGEN) CEO Getting Paid? Simply Wall St.
Jan-09-20 04:24PM	How Did Seattle Genetics, Inc. (SGEN) Compare Against Top Hedge Fund Stocks in 2019? Insider Monkey
Jan-06-20 08:00AM	Seattle Genetics to Present at the J.P. Morgan Healthcare Conference Business Wire
Dec-30-19 10:09AM	Astellas Acquires Xyphos to Boost Immuno-oncology Pipeline Zacks
Dec-26-19 08:13PM	What could you have made by investing $1,000 in these Washington companies a decade ago? American City Business Journals
02:47PM	Tech will drive change in health care throughout next decade American City Business Journals
Dec-24-19 01:12PM	Seattle Genetics Submits NDA to FDA for Tucatinib Combo Zacks

Seattle Genetics, Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; and PADCEV, an ADC composed of an anti-Nectin-4 monoclonal antibody for the treatment of metastatic urothelial cancers. It also develops Tucatinib, an investigational oral, small molecule TKI for HER2, a growth factor receptor; and Tisotumab Vedotin, an ADC composed of a human antibody that binds to tissue factor to treat various solid tumors, including cervical, ovarian, prostate, and bladder. In addition, the company develops ladiratuzumab vedotin, an ADC targeting LIV-1 and metastatic triple-negative breast cancer; SEA-BCMA, a clinical-stage non-fucosylated BCMA-directed antibody for patients with relapsed or refractory multiple myeloma. Seattle Genetics, Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; and biotechnology and pharmaceutical companies. Seattle Genetics, Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SIMPSON TODD E	Chief Financial Officer	Aug 03	Sale	165.72	20,000	3,314,418	143,181	Aug 05 07:14 PM
HIMES VAUGHN B	Chief Technical Officer	Jul 17	Option Exercise	15.46	8,000	123,680	199,840	Jul 21 07:48 PM
HIMES VAUGHN B	Chief Technical Officer	Jul 17	Sale	179.42	8,000	1,435,363	191,840	Jul 21 07:48 PM
SIEGALL CLAY B	President and CEO	Jul 08	Option Exercise	12.00	28,472	341,664	734,660	Jul 10 06:07 PM
SIEGALL CLAY B	President and CEO	Jul 08	Sale	175.08	28,472	4,984,808	718,339	Jul 10 06:07 PM
ROMP CHARLES R	EVP, Commercial	Jul 02	Sale	167.49	712	119,253	55,307	Jul 07 06:34 PM
SIMPSON TODD E	Chief Financial Officer	Jul 01	Sale	167.58	11,573	1,939,352	163,181	Jul 02 07:19 PM
LIU JEAN I	GC/EVP, Leg Affairs	Jun 19	Sale	165.00	9,877	1,629,705	63,597	Jun 22 07:46 PM
DANSEY ROGER D	Chief Medical Officer	Jun 17	Sale	158.89	2,162	343,523	109,608	Jun 19 05:54 PM
DANSEY ROGER D	Chief Medical Officer	Jun 16	Sale	157.15	838	131,692	111,770	Jun 17 07:24 PM
DANSEY ROGER D	Chief Medical Officer	Jun 15	Sale	157.15	4,984	783,236	112,608	Jun 17 07:24 PM
SIEGALL CLAY B	President and CEO	Jun 08	Option Exercise	12.00	28,472	341,664	724,939	Jun 10 06:57 PM
SIEGALL CLAY B	President and CEO	Jun 08	Sale	148.77	28,472	4,235,807	718,339	Jun 10 06:57 PM
BAKER BROS. ADVISORS LP	Director	May 15	Sale	160.00	1,750,000	280,000,000	4,082,851	May 19 06:03 PM
ROMP CHARLES R	EVP, Commercial	May 12	Option Exercise	15.46	6,942	107,323	59,517	May 14 06:54 PM
ROMP CHARLES R	EVP, Commercial	May 12	Sale	166.00	6,942	1,152,372	52,575	May 14 06:54 PM
ROMP CHARLES R	EVP, Commercial	May 08	Option Exercise	15.46	6,942	107,323	59,517	May 08 07:54 PM
SIEGALL CLAY B	President and CEO	May 08	Option Exercise	12.00	28,472	341,664	728,603	May 12 07:51 PM
SIEGALL CLAY B	President and CEO	May 08	Sale	161.01	28,472	4,584,311	718,339	May 12 07:51 PM
ROMP CHARLES R	EVP, Commercial	May 08	Sale	163.02	6,942	1,131,667	52,575	May 08 07:54 PM
BAKER BROS. ADVISORS LP	Director	May 08	Sale	158.50	500,000	79,250,000	4,230,539	May 08 05:47 PM
DANSEY ROGER D	Chief Medical Officer	May 07	Option Exercise	65.11	11,912	775,590	129,145	May 08 07:42 PM
DANSEY ROGER D	Chief Medical Officer	May 07	Sale	164.50	11,912	1,959,526	117,233	May 08 07:42 PM
BAKER BROS. ADVISORS LP	Director	May 07	Sale	164.41	168,244	27,660,947	4,272,736	May 08 05:47 PM
SIEGALL CLAY B	President and CEO	May 06	Sale	165.23	25,402	4,197,062	718,339	May 07 07:59 PM
WELCH DANIEL G	Director	May 06	Sale	164.79	15,000	2,471,919	55,263	May 07 07:59 PM
BAKER BROS. ADVISORS LP	Director	May 06	Sale	165.05	390,072	64,379,473	4,286,935	May 08 05:47 PM
SIMPSON TODD E	Chief Financial Officer	May 05	Option Exercise	22.15	39,059	865,277	188,563	May 06 06:32 PM
AKKARAJU SRINIVAS	Director	May 05	Option Exercise	20.06	8,500	170,510	48,668	May 07 07:58 PM
SIEGALL CLAY B	President and CEO	May 05	Sale	166.08	24,598	4,085,341	743,741	May 07 07:59 PM
WELCH DANIEL G	Director	May 05	Sale	166.73	20,000	3,334,641	70,263	May 07 07:59 PM
AKKARAJU SRINIVAS	Director	May 05	Sale	167.26	8,500	1,421,710	40,168	May 07 07:58 PM
ROMP CHARLES R	EVP, Commercial	May 05	Sale	166.18	5,056	840,226	52,575	May 07 07:59 PM
SIMPSON TODD E	Chief Financial Officer	May 05	Sale	162.94	26,867	4,377,596	161,696	May 06 06:32 PM
SIMPSON TODD E	Chief Financial Officer	May 04	Option Exercise	12.00	14,167	170,004	175,863	May 06 06:32 PM
SIMPSON TODD E	Chief Financial Officer	May 04	Sale	147.00	14,167	2,082,556	161,696	May 06 06:32 PM
LIPPMAN MARC E	Director	May 04	Sale	152.03	1,000	152,030	130,313	May 06 06:19 PM
BAKER BROS. ADVISORS LP	Director	Apr 23	Option Exercise	12.76	35,000	446,600	45,860,149	Apr 24 04:25 PM
SIEGALL CLAY B	President and CEO	Apr 08	Option Exercise	12.00	28,472	341,664	779,866	Apr 10 07:31 PM
SIEGALL CLAY B	President and CEO	Apr 08	Sale	120.01	28,472	3,416,814	758,784	Apr 10 07:31 PM
SIEGALL CLAY B	President and CEO	Mar 09	Option Exercise	12.00	28,472	341,664	768,581	Mar 11 06:51 PM
SIEGALL CLAY B	President and CEO	Mar 09	Sale	110.09	28,472	3,134,578	758,784	Mar 11 06:51 PM
HIMES VAUGHN B	Chief Technical Officer	Mar 06	Option Exercise	13.51	8,000	108,117	193,172	Mar 10 08:12 PM
HIMES VAUGHN B	Chief Technical Officer	Mar 06	Sale	114.91	8,000	919,292	188,674	Mar 10 08:12 PM
DANSEY ROGER D	Chief Medical Officer	Feb 18	Sale	116.33	350	40,716	107,659	Feb 20 05:33 PM
SIEGALL CLAY B	President and CEO	Feb 10	Option Exercise	12.00	28,472	341,664	768,723	Feb 12 05:38 PM
SIEGALL CLAY B	President and CEO	Feb 10	Sale	114.61	28,472	3,263,110	758,784	Feb 12 05:38 PM
DANSEY ROGER D	Chief Medical Officer	Feb 03	Sale	108.51	727	78,887	108,009	Feb 05 06:08 PM
SIEGALL CLAY B	President and CEO	Jan 08	Option Exercise	12.00	28,472	341,664	785,937	Jan 10 07:08 PM
SIEGALL CLAY B	President and CEO	Jan 08	Sale	111.32	28,472	3,169,433	758,784	Jan 10 07:08 PM
WELCH DANIEL G	Director	Jan 07	Option Exercise	12.76	17,500	223,300	90,263	Jan 09 08:32 PM
DANSEY ROGER D	Chief Medical Officer	Dec 16	Sale	114.07	2,000	228,140	101,146	Dec 17 06:48 PM
SIEGALL CLAY B	President and CEO	Dec 09	Option Exercise	12.00	28,472	341,664	773,011	Dec 10 07:15 PM
SIEGALL CLAY B	President and CEO	Dec 09	Sale	114.56	28,472	3,261,641	755,684	Dec 10 07:15 PM
HIMES VAUGHN B	Chief Technical Officer	Dec 06	Option Exercise	12.00	8,000	96,000	195,518	Dec 10 07:14 PM
HIMES VAUGHN B	Chief Technical Officer	Dec 06	Sale	117.16	8,000	937,265	187,518	Dec 10 07:14 PM
DANSEY ROGER D	Chief Medical Officer	Nov 25	Option Exercise	65.11	5,000	325,550	108,146	Nov 27 05:32 PM
DANSEY ROGER D	Chief Medical Officer	Nov 25	Sale	121.48	5,000	607,388	103,146	Nov 27 05:32 PM
AKKARAJU SRINIVAS	Director	Nov 21	Option Exercise	19.02	17,500	332,850	52,726	Nov 22 06:35 PM
AKKARAJU SRINIVAS	Director	Nov 21	Sale	119.78	17,500	2,096,120	40,168	Nov 22 06:35 PM
LIPPMAN MARC E	Director	Nov 18	Option Exercise	15.89	35,000	556,150	148,813	Nov 20 06:41 PM
DANSEY ROGER D	Chief Medical Officer	Nov 18	Option Exercise	65.11	5,000	325,550	108,146	Nov 20 06:45 PM
DANSEY ROGER D	Chief Medical Officer	Nov 18	Sale	116.00	5,000	580,000	103,146	Nov 20 06:45 PM
LIPPMAN MARC E	Director	Nov 18	Sale	115.80	35,000	4,053,000	131,313	Nov 20 06:41 PM
SIEGALL CLAY B	President and CEO	Nov 08	Option Exercise	12.00	28,472	341,664	776,483	Nov 12 06:24 PM
SIEGALL CLAY B	President and CEO	Nov 08	Sale	107.61	28,472	3,063,816	755,684	Nov 12 06:24 PM
SIEGALL CLAY B	President and CEO	Oct 08	Option Exercise	12.00	28,472	341,664	770,104	Oct 10 06:55 PM
SIEGALL CLAY B	President and CEO	Oct 08	Sale	82.47	28,472	2,348,061	755,684	Oct 10 06:55 PM
GRYSKA DAVID W	Director	Oct 01	Option Exercise	15.89	5,000	79,450	50,513	Oct 03 07:38 PM
GRYSKA DAVID W	Director	Oct 01	Sale	85.09	5,000	425,450	48,013	Oct 03 07:38 PM
SIMPSON TODD E	Chief Financial Officer	Sep 30	Sale	85.00	15,000	1,275,000	157,567	Oct 02 06:12 PM
LIU JEAN I	GC/EVP, Leg Affairs	Sep 30	Sale	86.00	7,432	639,152	70,688	Oct 02 06:10 PM
DANSEY ROGER D	Chief Medical Officer	Sep 25	Sale	73.80	3,000	221,415	103,146	Sep 27 06:12 PM
SIEGALL CLAY B	President and CEO	Sep 09	Option Exercise	12.00	28,472	341,664	774,374	Sep 10 07:29 PM
SIEGALL CLAY B	President and CEO	Sep 09	Sale	68.33	28,472	1,945,531	755,684	Sep 10 07:29 PM
HIMES VAUGHN B	See Remarks	Sep 03	Sale	70.80	5,692	402,990	187,518	Sep 04 09:45 PM
SIEGALL CLAY B	See Remarks	Sep 03	Sale	70.80	9,693	686,257	755,684	Sep 04 09:46 PM
DANSEY ROGER D	See Remarks	Sep 03	Sale	70.80	922	65,277	106,146	Sep 04 09:43 PM
SIMPSON TODD E	See Remarks	Sep 03	Sale	70.80	2,092	148,112	172,567	Sep 04 09:42 PM
HIMES VAUGHN B	See Remarks	Aug 30	Option Exercise	12.00	8,000	96,000	201,210	Sep 04 09:45 PM
HIMES VAUGHN B	See Remarks	Aug 30	Sale	72.86	8,000	582,859	193,210	Sep 04 09:45 PM
LIU JEAN I	GC/EVP, Leg Affairs	Aug 28	Sale	73.22	6,013	440,242	60,904	Aug 30 04:35 PM
SIEGALL CLAY B	President and CEO	Aug 28	Sale	73.21	28,951	2,119,636	717,343	Aug 30 04:35 PM
SIMPSON TODD E	Chief Financial Officer	Aug 28	Sale	73.21	5,909	432,624	153,371	Aug 30 04:36 PM
HIMES VAUGHN B	Chief Technical Officer	Aug 28	Sale	73.21	6,836	500,496	175,197	Aug 30 04:35 PM
SIMPSON TODD E	Chief Financial Officer	Aug 20	Sale	80.00	12,500	1,000,000	159,280	Aug 22 05:49 PM
LIU JEAN I	GC/EVP, Leg Affairs	Aug 20	Sale	80.00	3,716	297,280	66,917	Aug 22 05:47 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience